March 25, 2021

TICA Distribution Full Report

By Sofia Imad, Shilpa Rao, Vibhav Mariwala, Mrunalini Chaudhari, Mahesh Kalsekar, Rohit Bajoria, Supriya Shinde

With a vaccine sector valued at ~INR 95 billion and growing at a CAGR of 18%, India is a global leader in vaccine manufacturing and production. Established in 1978, India’s Universal Vaccination Programme (UIP) is the World’s largest public vaccination program, and provides twelve free vaccines against critical diseases to nearly 56 million children and pregnant women annually. The UIP’s concerted efforts over nearly four decades have resulted in gradually increasing vaccine coverage, reaching 62% vaccination coverage with the government’s ‘Mission Indradhanush’ expected to accelerate the increase in vaccine coverage. However, will this infrastructure and capacity hold up to be able to provide the ambitious 600M doses in Phase 1 by July 31st and what role is the private sector currently playing and looking to play in this campaign rollout - is what we attempted to answer.


To understand this better, IDFC Institute partnered with Pharmarack Technologies Pvt. Ltd., a B2B healthcare service provider to unpack and assess India’s COVID-19 vaccine distribution capacity and preparedness (both private and public sector), including - vaccine equipment capacities, cold storage capacities, transport and logistical preparedness and state level disparities in their readiness to roll-out the campaign. We did this through extensive secondary research, 13 interviews conducted with top vaccine manufacturers, transportation and logistics companies involved in pharma and vaccine transport, nonprofits and multilaterals working in public health, FMCG companies involved in cold-chain transport and storage and subject matter experts.


Access the full report and executive summary of the study from the sidebar of this page.


To explore an interactive version of the findings of this report and to explore other tracks of The Indian COVID Alliance’s (TICA), click here.

In : Reports
x Close Window

Please verify your email address to access this content